financetom
Business
financetom
/
Business
/
Shopify Merchant Adds Accelerating, Take Rates Likely Under Pressure, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Shopify Merchant Adds Accelerating, Take Rates Likely Under Pressure, Oppenheimer Says
Sep 29, 2024 4:50 AM

11:20 AM EDT, 09/23/2024 (MT Newswires) -- Shopify ( SHOP ) is accelerating new merchant additions on a sequential basis in the third quarter but growth initiates will likely cap near-term margins and take rates, Oppenheimer said in a note emailed Monday.

The e-commerce platform is investing marketing dollars in acquiring new merchants as it seeks to capture market share ahead of a possible macroeconomic rebound, a group of analysts including Ken Wong wrote in the note.

"Effective marketing equates with growing merchants which we believe is slightly outpacing (the second quarter)," Wong said. Outperform-rated Shopify's ( SHOP ) gross merchandise volume, which measures the total dollar amount of orders facilitated through Shopify's ( SHOP ) merchants, rose 22% year over year to $67.25 billion in the second quarter.

"Management is not optimizing for near-term take rate with elevated enterprise, (point of sale) and international growth sources of pressure before progressing upwards over time with product attach," according to Wong.

However, Shopify's ( SHOP ) expanded partnership with PayPal ( PYPL ) could offer the former negotiating leverage, according to Oppenheimer. Under the revised deal, PayPal ( PYPL ) will become an additional online card processor for Shopify Payments in the US. PayPal Wallet transactions now factoring into gross payments volume should be additive to take rate and revenue, the analysts said.

Gross payments volume grew to 61% of GMV in the second quarter from 58% in the same period of 2023, Shopify ( SHOP ) reported last month.

Oppenheimer is modeling for adjusted earnings per share of $0.31 in the third quarter, implying growth from $0.24 the year earlier and from the $0.26 Shopify ( SHOP ) reported last quarter. Analysts surveyed by Capital IQ are estimating normalized EPS of $0.27 on average for the ongoing quarter. The brokerage's revenue target marks sequential and year-over-year growth to $2.1 billion, which is in line with consensus views.

Price: 79.60, Change: +0.88, Percent Change: +1.12

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Silgan's Bid to Acquire Gerresheimer Rejected
Market Chatter: Silgan's Bid to Acquire Gerresheimer Rejected
Apr 17, 2026
06:54 AM EDT, 04/17/2026 (MT Newswires) -- Silgan's ( SLGN ) bid to take over German medical packaging maker Gerresheimer has been rejected, Reuters reported Friday, citing sources familiar with the matter. Talks between the two companies have concluded, the sources reportedly said. Silgan ( SLGN ) made a non-binding offer of 41 euros ($48.36) per share, Reuters previously reported....
Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week
Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week
Apr 17, 2026
April 17 (Reuters) - Eli Lilly's ( LLY ) newly launched obesity pill was prescribed 1,390 times in the U.S. as of the week ended April 10, according to an analyst who cited IQVIA data. Novo Nordisk's oral Wegovy had hit 3,071 U.S. prescriptions in the first four days after its launch on January 5. Investors have been closely watching...
Bruker's Division Rolls Out MyGenius PRO Diagnostics System in Europe
Bruker's Division Rolls Out MyGenius PRO Diagnostics System in Europe
Apr 17, 2026
06:53 AM EDT, 04/17/2026 (MT Newswires) -- Bruker's ( BRKR ) Bruker Microbiology & Infection Diagnostics division said Friday it has rolled out molecular diagnostics system MyGenius PRO in Europe. The new diagnostics system is based on polymerase chain reaction, developed to diagnose infectious diseases, according to the division. Bruker Microbiology said the MyGenius PRO system automates the complete workflow...
Lilly's Foundayo hits 1,390 prescriptions in debut week
Lilly's Foundayo hits 1,390 prescriptions in debut week
Apr 17, 2026
April 17 (Reuters) - Eli Lilly's ( LLY ) newly launched obesity pill was prescribed 1,390 times in the U.S. as of the week ended April 10, according to an analyst who cited IQVIA data. Novo Nordisk's oral Wegovy had hit 3,071 U.S. prescriptions in the first four days after its launch on January 5. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved